2012, ISBN: 9783642282959
Springer, Gebundene Ausgabe, Auflage: 2012, 244 Seiten, Publiziert: 2012-03-22T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 8 black & white tables, biography, 1.18 kg, Rechtsmedizin, M… Meer...
amazon.de The Cotswold Library Gebraucht, wie neu. Verzendingskosten:Auf Lager. Die angegebenen Versandkosten können von den tatsächlichen Kosten abweichen. (EUR 3.00) Details... |
2012, ISBN: 9783642282959
Springer, Gebundene Ausgabe, Auflage: 2012, 244 Seiten, Publiziert: 2012-03-22T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 8 black & white tables, biography, 1.18 kg, Rechtsmedizin, M… Meer...
amazon.de Verzendingskosten:Die angegebenen Versandkosten können von den tatsächlichen Kosten abweichen. (EUR 3.00) Details... |
2012, ISBN: 3642282954
2012 Gebundene Ausgabe Krebs (Krankheit), Tumor / Krebs, MitogenActivatedProteinKinase(MAPK); Rafkinases; Biomarkers; chemicallibrary; clinicaltrialdesign; drugdevelopment; drugefficacy… Meer...
Achtung-Buecher.de MARZIES.de Buch- und Medienhandel, 14621 Schönwalde-Glien Verzendingskosten:Versandkostenfrei innerhalb der BRD. (EUR 0.00) Details... |
2012, ISBN: 9783642282959
[PU: Springer Berlin], Buchschnitt verkürzt - gepflegter, sauberer Zustand - 2012 Ausgabejahr 11863221/12, DE, [SC: 0.00], gebraucht; sehr gut, gewerbliches Angebot, 2012, PayPal, Klarna-… Meer...
booklooker.de |
2012, ISBN: 9783642282959
Buch, Hardcover, 2012, [PU: Springer Berlin], Springer Berlin, 2012
lehmanns.de Verzendingskosten:sofort lieferbar. (EUR 0.00) Details... |
Therapeutic Kinase Inhibitors (Current Topics in Microbiology and Immunology, 355, Band 355) - gebonden uitgave, pocketboek
2012, ISBN: 9783642282959
Springer, Gebundene Ausgabe, Auflage: 2012, 244 Seiten, Publiziert: 2012-03-22T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 8 black & white tables, biography, 1.18 kg, Rechtsmedizin, M… Meer...
2012, ISBN: 9783642282959
Springer, Gebundene Ausgabe, Auflage: 2012, 244 Seiten, Publiziert: 2012-03-22T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 8 black & white tables, biography, 1.18 kg, Rechtsmedizin, M… Meer...
2012
ISBN: 3642282954
2012 Gebundene Ausgabe Krebs (Krankheit), Tumor / Krebs, MitogenActivatedProteinKinase(MAPK); Rafkinases; Biomarkers; chemicallibrary; clinicaltrialdesign; drugdevelopment; drugefficacy… Meer...
2012, ISBN: 9783642282959
[PU: Springer Berlin], Buchschnitt verkürzt - gepflegter, sauberer Zustand - 2012 Ausgabejahr 11863221/12, DE, [SC: 0.00], gebraucht; sehr gut, gewerbliches Angebot, 2012, PayPal, Klarna-… Meer...
2012, ISBN: 9783642282959
Buch, Hardcover, 2012, [PU: Springer Berlin], Springer Berlin, 2012
Bibliografische gegevens van het best passende boek
Gedetalleerde informatie over het boek. - Therapeutic Kinase Inhibitors (Current Topics in Microbiology and Immunology, 355, Band 355)
EAN (ISBN-13): 9783642282959
ISBN (ISBN-10): 3642282954
Gebonden uitgave
Verschijningsjaar: 2012
Uitgever: Mellinghoff, Ingo K. Sawyers, Charles L. Springer
234 Bladzijden
Gewicht: 0,492 kg
Taal: Englisch
Boek bevindt zich in het datenbestand sinds 2007-02-22T17:09:48+01:00 (Amsterdam)
Detailpagina laatst gewijzigd op 2023-06-06T14:17:49+02:00 (Amsterdam)
ISBN/EAN: 3642282954
ISBN - alternatieve schrijfwijzen:
3-642-28295-4, 978-3-642-28295-9
alternatieve schrijfwijzen en verwante zoekwoorden:
Auteur van het boek: mell, sawyer, mellin, melling
Titel van het boek: kina kina, ingo, microbiology
Gegevens van de uitgever
Auteur: Ingo K. Mellinghoff; Charles L. Sawyers
Titel: Current Topics in Microbiology and Immunology; Therapeutic Kinase Inhibitors
Uitgeverij: Springer; Springer Berlin
234 Bladzijden
Verschijningsjaar: 2012-03-22
Berlin; Heidelberg; DE
Gedrukt / Gemaakt in
Taal: Engels
160,49 € (DE)
164,99 € (AT)
177,00 CHF (CH)
POD
X, 234 p.
BB; Hardcover, Softcover / Medizin/Nichtklinische Fächer; Onkologie; Verstehen; Medizin, Gesundheit; Mitogen Activated Protein Kinase (MAPK); Raf kinases; biomarkers; chemical library; clinical trial design; drug development; drug efficacy; epigenetics; gastrointestinal stromal tumor (GIST); genetically engineered mouse models (GEMMs); glioblastoma; lung adenocarcinoma; lung cancer; melanoma; myeloproliferative neoplasms; small molecules; Cancer Biology; EA; BC
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.
This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.
This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors hope these lessons will be instructive for the novice as well as the expert.
Includes supplementary material: sn.pub/extras
Andere boeken die eventueel grote overeenkomsten met dit boek kunnen hebben:
Laatste soortgelijke boek:
9783642445804 Therapeutic Kinase Inhibitors (Sawyers, Charles L. (Herausgeber); Mellinghoff, Ingo K. (Herausgeber))
< naar Archief...